Pharmacovigilance and Safety Monitoring Services in Lebanon
Pharmacovigilance in Lebanon is becoming more structured as the country strengthens how medicinal product safety is monitored after authorization.
The Lebanese Ministry of Public Health (MoPH), through the Lebanese National Pharmacovigilance Program (LNPVP), oversees the national framework of pharmacovigilance. Marketing Authorization Holders (MAHs) must make sure that the systems permit the gathering of safety information and are evaluated, as well as reported on, throughout the life cycle of the products.
Most significant changes occurred in January 2026, when the MoPH completed a variety of components of the Lebanese Guideline on Good Pharmacovigilance Practices (LGVP). They include the pharmacovigilance system and the requirements for PSMF/PSSF, the management of risk, adverse-reaction reporting, PSURs, post-authorization safety studies, safety communication, and risk-minimization measures.
The MoPH has since extended the effective implementation timeframe to the LGVP modules until Q3 2027. For companies that operate in Lebanon, the planning of pharmacovigilance is increasingly crucial. Global safety systems have to integrate with national regulations and have clear roles for reporting on cases as well as documents on safety, pv risk management, and local supervision.
DDReg provides Pharmacovigilance Services in Lebanon to support pharmaceutical and life sciences companies across safety case management, aggregate reporting , signal management, risk management, , literature monitoring services , PV-system support, and compliance activities.
Understanding Lebanon’s Pharmacovigilance Framework
Lebanon’s pharmacovigilance system operates under the Ministry of Public Health, with the Lebanese National Pharmacovigilance Program responsible for strengthening medicine-safety monitoring and adverse-event reporting.
The finalized LGVP framework published in January 2026 includes several areas that directly affect MAHs:
- Module I – Pharmacovigilance systems and quality systems
- Module II – Pharmacovigilance System Master File (PSMF) and Pharmacovigilance Sub-System File (PSSF)
- Module V – Risk Management System
- Module VI – Collection, management, and submission of suspected adverse-reaction reports
- Module VII – Periodic Safety Update Reports (PSURs)
- Module VIII – Post-Authorization Safety Studies (PASS)
- Module XV – Safety Communication
- Module XVI – Risk-Minimization Measures and effectiveness indicators
The framework is particularly relevant for multinational companies because pharmacovigilance activities in Lebanon may operate as part of a wider global PV system.
MoPH guidance states that multinational or international MAHs should clearly describe how their global pharmacovigilance system and national pharmacovigilance sub-system work together. This includes the activities carried out locally, those handled globally, and the responsibilities of the relevant local safety function.
For companies seeking Drug Safety Services Lebanon, the practical challenge is therefore not simply reporting adverse events. It is making sure that local and global safety processes remain connected and that information moves through the system consistently.
What Shapes the Pharmacovigilance Pathway in Lebanon?
The pharmacovigilance pathway depends on the product, the MAH’s operating model, the global safety system already in place, and the safety obligations that apply during the product lifecycle.
| PV Factor | What Needs to Be Considered |
|---|---|
| MAH & Operating Structure | Whether the company operates nationally or as part of a multinational/global pharmacovigilance system. |
| PV System Documentation | The applicable PSMF/PSSF structure and how local pharmacovigilance activities connect with the global system. |
| Safety Case Management | Processes for receiving, assessing, documenting, following up, and reporting suspected adverse reactions. |
| Aggregate Safety Reporting | Applicable PSUR and other periodic benefit-risk reporting responsibilities. |
| Risk Management | Identification and management of known, potential, and emerging risks through appropriate risk-management measures. |
| Signal & Safety Monitoring | Ongoing review of ICSRs, literature, aggregate data, regulatory information, and other potential signal sources. |
| Post-Authorization Activities | PASS, safety communications, risk-minimization activities, and other post-marketing safety obligations where applicable. |
An early review of these areas can show whether an existing global pharmacovigilance system is ready to support Lebanon or whether local processes, documentation, responsibilities, or reporting workflows need to be strengthened.
For organizations considering Pharmacovigilance Consulting Lebanon, this assessment is particularly useful when Lebanon is being added to an existing multi-country safety system.
How the Safety Reporting Registration Process Works in Lebanon
Once the pharmacovigilance system and responsibilities are established, safety information needs to move through a controlled reporting process.
1. Safety Information Collection
Potential adverse reactions may come from spontaneous reports, healthcare professionals, patients, literature, clinical activities, partners, or other safety sources.
The first priority is to capture enough information to determine whether a valid safety case exists and whether follow-up is required.
2. Case Assessment and Processing
Relevant cases are reviewed for seriousness, expectedness, causality, medical significance, and completeness.
Coding, duplicate checks, medical review, follow-up, and quality control help ensure that case information is suitable for regulatory reporting and ongoing safety evaluation.
3. ICSR Reporting
For MAHs, Lebanon requires safety reports to be submitted using internationally recognized ICH standards. MoPH guidance refers to XML reporting in line with ICH E2B(R2) or ICH E2B(R3).
Under LGVP Module VI, the published reporting timelines include:
| Type of ICSR | Reporting Timeline |
|---|---|
| Serious ICSR | 15 days |
| Follow-up for serious ICSR | 15 days |
| Non-serious ICSR | 90 days |
| Follow-up for non-serious ICSR | 90 days |
Certain situations, including suspected transmission of an infectious agent and specified lack-of-efficacy cases involving critical medicines, are also subject to the 15-day timeframe under the guidance.
4. Aggregate Safety Review
Individual cases provide only one part of the safety picture.
MAHs also need to periodically assess accumulated safety information through documents such as PSURs, where applicable, to evaluate whether the overall benefit-risk profile has changed.
5. Signal and Risk Evaluation
New safety information may require further assessment to determine whether it represents a new signal or a change in a known risk.
This may lead to further monitoring, risk-management activities, safety communication, labeling considerations, or additional post-authorization measures.
6. Ongoing PV System Management
Pharmacovigilance responsibilities continue throughout the product lifecycle.
The PV system, supporting procedures, safety documents, reporting processes, and risk-management activities should remain current as products, safety information, and regulatory expectations evolve.
How DDReg Supports Pharmacovigilance Activities in Lebanon
DDReg supports pharmaceutical and life sciences companies with established pharmacovigilance capabilities across case management, safety surveillance, reporting, risk management, and PV audit compliance.
-
ICSR Processing and Submission
-
Literature Monitoring
-
Aggregate Safety Reporting
-
Risk Management
-
Signal Management
-
PV System and Quality Support
-
Audit and Inspection Readiness
-
QPPV and PV Oversight Support
Through Pharmacovigilance Consulting Lebanon, DDReg can help companies connect local pharmacovigilance requirements with wider global safety operations while maintaining consistent safety processes across the product lifecycle.
Why Partner with DDReg for Pharmacovigilance Support in Lebanon
Running an effective pharmacovigilance system requires more than processing individual cases. Case management, literature surveillance, aggregate reporting, signal detection, risk management, quality oversight, and regulatory compliance all need to work together.
DDReg brings these activities into a coordinated drug-safety framework for pharmaceutical and life sciences companies operating across multiple markets.
For companies seeking a Pharmacovigilance Consultant Lebanon, DDReg combines global pharmacovigilance expertise with an understanding of evolving Lebanese MoPH and LGVP expectations.
Our Capabilities Include
- 17+ years of global regulatory expertise
- ICSR processing and regulatory submission support
- E2B(R3)-compliant safety operations
- Literature monitoring
- Global pharmacovigilance and drug-safety expertise
- Aggregate safety report preparation
- Signal detection and management
- Risk Management Plan support
- PSMF and PV-system documentation support
- QPPV/RPPV support for applicable operations
- PV audits and inspection readiness
- Multi-country pharmacovigilance support
- Post-marketing safety surveillance
DDReg’s global pharmacovigilance offering confirms these capabilities across ICSR management, literature monitoring, risk management, audit and compliance, signal management, QPPV services, and aggregate safety reporting.
Global Reach Explorer
Find Your Solution
Our Pharmacovigilance (PV) Services Expertise
ICSR Case Processing and Submission
Our advanced Individual Case Safety Report (ICSR) Pharmacovigilance Services are dedicated to ensuring patient safety through precise case handling....
Literature Monitoring
DDReg’s Literature Monitoring Services offer advanced pharmacovigilance literature screening for drug safety. We help Marketing...
Risk Management
Our expert risk management solutions ensure patient safety by proactively addressing potential hazards in pharmaceutical...
Audit and Compliance
Our specialized services ensure that pharmacovigilance systems across the drug development pipeline meet strict regulatory...
Pharmacovigilance Signal Management Services
DDReg’s specialized pharmacovigilance services ensure that potential adverse events are identified and addressed promptly...
QPPV Services
DDReg’s expert team provides comprehensive QPPV services designed to strengthen your pharmacovigilance system. We ensure that...
